Recorded device evidence

Stat Profile Prime ES Comp Plus Analyzer System (K191626): indications, design and recorded evidence

The acquired K191626 file contains product-specific indications and users, design and operating principle, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 1 selected decisions under primary code JFP. 1 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K191626 ↗ · this pageStat Profile Prime ES Comp Plus Analyzer System2019-06-18 → 2019-08-1659Traditional
K230300 ↗i-STAT CG8+ cartridge with the i-STAT 1 System2023-02-03 → 2023-10-27266Traditional
K191360 ↗i-STAT CHEM8+ cartridge with the i-STAT 1 System2019-05-21 → 2020-02-14269Traditional
K152327 ↗EasyLyte Na/K/Cl/Ca Analyzer2015-08-18 → 2016-12-01471Traditional
K984299 ↗AVL OPTI CRITICAL CARE ANALYZER1998-12-01 → 1998-12-1110Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K191626 · PDF page 3 ↗ Source 2

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K191626 · PDF page 4 ↗ Source 3

The Stat Profile Prime ES Comp Plus Analyzer is a small, low cost blood electrolyte analyzer. It
consists of the analyzer, sensor cartridges, and thermal paper for an onboard printer.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Performance evidence actually described

K191626 · PDF page 7 ↗ Source 4

Performance testing was completed to demonstrate that the Stat Profile Prime ES Comp Plus
Analyzer is substantially equivalent in performance, safety and efficacy to the predicate Nova Stat
Profile pHOx Ultra Blood Gas Analyzer (K110648).

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK191626 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryStat Profile Prime ES Comp Plus Analyzer System [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantNova Biomedical Corporation [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeJFP [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2019-08-16 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2019-06-18 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

Work packages and dependencies

What needs to happen first

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[76681] · record 72e7df304468147c9e522db68f4d54a99dff8fd754dc6f0d4c2d98c83bd64226
  • [5] Complete results array / fda-decision-context:K191626 · record whole dataset partition

FDA 510(k) summary — K191626 ↗

Mon, 09 Sep 2019 11:38:16 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 2f98a62369fb3e7295c9aa9421e5542b97fe9337c520e960e10cb85653db2976

  • [2] PDF page 3 · record 25f828aaabd1e1e54f29c9fd8350623f55cd94d2a434c44323e5a352055f00f2
  • [3] PDF page 4 · record 439c5530f8f32d327070b59bb70491a58583eea8a084b46967b4ee838267929a
  • [4] PDF page 7 · record 9ef318f62df4d5f5cd742577ec163a294e74508a3ef2467e242bce20614adbfb

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services

Packaging + Shelf-life + Distribution Testing